OncoLux Inc.

have merged to form

Bringing together the power of

Intraoperative

Enhanced Cancer

Visualization

Optical
Photodynamic
Therapy

to create a new class of

Intraoperative / In-Situ Adjuvant Therapy for Residual Cancer following Resection Surgery

We didn't get it all

These are

Five Dreaded Words

to every cancer surgery patient

Surgical oncologists perform a delicate balance, completing tumor resection while aiming to preserve healthy tissue and functionality.

In these delicate procedures, some cancer gets missed, and some are deemed unresectable due to important local anatomical features and structures.

Either way patients left with residual cancer following surgery will generally have a poorer prognosis.

No one wants this outcome, and we believe it doesn’t need to be this way…

See and treat residual cancer in-situ

to ensure better outcomes.

Learn More

OncoLux’s new Optical Theranostic system combines intraoperative enhanced visualization of residual cancer with optical photodynamic therapy, allowing surgeons to

Be the first to know